EUCTR2009-013029-41-IT
Active, not recruiting
Not Applicable
Proteomic profile analysis to classify advanced pancreatic adenocarcinoma patients for clinical outcome after treatment with PDXG (cisplatin, docetaxel, capecitabine, gemcitabine) or PEXG (cisplatin, epirubicin, capecitabine, gemcitabine) regimen. - ND
FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR0 sitesJune 11, 2009
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- patients affected by adenocarcinoma at stage III or IV who are candidate to receive upfront chemotherapy according to PDXG or PEXG regimen.
- Sponsor
- FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR
- Status
- Active, not recruiting
- Last Updated
- 14 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •to include patients with cytological or histological diagnosis of pancreatic adenocarcinoma at stage III or IV who are candidate to receive upfront chemotherapy according to PDXG or PEXG regimen.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range
- •F.1\.3 Elderly (\>\=65 years) no
- •F.1\.3\.1 Number of subjects for this age range
Exclusion Criteria
- •patients withouth cytological or histological diagnosis of pancreatic adenocarcinoma at stage III or IV who are candidate to receive upfront chemotherapy according to PDXG or PEXG regimen.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Proteomic analysis for establishing a biomarker panel for the onset of Adult T-cell Leukemia (ATL)JPRN-UMIN000038467niversity of the Ryukyus85
Completed
Not Applicable
Proteomics and pancreatic cystic neoplasms: a pilot studyISRCTN10626053Geneva University Hospital (Switzerland)10
Completed
Not Applicable
Study of proteomics for identification of novel prognostic biomarkers in patients with hepatocellular carcinoma and intrahepatic cholangiocarcinoma undergoing surgical resectioHepatocellular carcinoma and Intrahepatic cholangiocarcinomaHepatocellular carcinoma, Intrahepatic cholangiocarcinoma, Biomarkers, Proteomics, PrognosisTCTR20220113002Ratchadapisek Research Funds115
Active, not recruiting
Not Applicable
Evaluación mediante proteómica de biomarcadores proteicos asociados con el tratamiento con Eplerenona versus espironolactona en pacientes post-infarto agudo de miocardio, diabéticos con hipertensión arterial no controlada y disfunción ventricular sistólica leve”Identification of proteomic biomarkers associated with eplerenone treatment versus spironolactone in post-acute coronary syndrome patients, with non-controlled arterial hypertension and ventricular dysfunction - PROMETEODisfunción ventricular leve-moderada post-infarto agudo de miocardio en pacientes diabéticos con hipertensión arterial no controlada.Low-moderate ventricular dysfunction in post-acute coronary syndrome patients with diabetes and non-controlled arterial hypertension.EUCTR2008-001192-29-ESFundación Investigación y Desarrollo en el Area Cardiovascular
Active, not recruiting
Not Applicable
Análisis proteómico del plasma y plaquetas de pacientes con Diabetes tipo II con enfermedad arterial coronaria estabilizada. Modificación por el tratamiento con clopidogrel. Estudio piloto. - CIDDiabetes Mellitus Tipo II con enfermedad coronaria estabilizadaEUCTR2006-002292-40-ESFundación para la Investigación y Desarrollo en el Área Cardiovascular (FIC)